Designing Paclitaxel Drug Delivery Systems Aimed at Improved Patient Outcomes: Current Status and Challenges

Figure 3

Cumulative in vitro release of paclitaxel from PLGA-Nps (Resomer RG 502). PLGA-Nps containing paclitaxel 1% (w/w) were diluted in PBS, incubated at 37°C, and shaken horizontally. At preselected time intervals, the released drug was separated by ultracentrifugation and the residual amount of paclitaxel present in the nanospheres was determined by HPLC. (reproduced with permission from Fonseca et al., [33]).